Audentes Therapeutics Inc (NASDAQ:BOLD)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $59.48 and last traded at $59.32, with a volume of 2113154 shares changing hands. The stock had previously closed at $59.25.
Several research firms have commented on BOLD. Citigroup upgraded Audentes Therapeutics from a “sell” rating to a “neutral” rating and upped their price objective for the stock from $30.00 to $60.00 in a research report on Tuesday, December 3rd. BidaskClub lowered shares of Audentes Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, November 8th. Guggenheim cut shares of Audentes Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 3rd. Wells Fargo & Co decreased their target price on shares of Audentes Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Tuesday, December 3rd. Finally, Chardan Capital reissued a “neutral” rating and set a $60.00 price target on shares of Audentes Therapeutics in a report on Wednesday, December 4th. One equities research analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and three have issued a buy rating to the company’s stock. Audentes Therapeutics presently has an average rating of “Hold” and an average target price of $47.20.
The firm has a market capitalization of $2.71 billion, a price-to-earnings ratio of -17.45 and a beta of 1.77. The company has a 50 day moving average price of $32.15 and a two-hundred day moving average price of $33.80.
Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.07. During the same period in the previous year, the business posted ($0.97) EPS. As a group, equities research analysts anticipate that Audentes Therapeutics Inc will post -4.13 earnings per share for the current year.
In related news, Director Louis G. Lange sold 10,000 shares of Audentes Therapeutics stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $32.16, for a total value of $321,600.00. Following the sale, the director now directly owns 276,044 shares in the company, valued at approximately $8,877,575.04. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Matthew R. Patterson sold 14,426 shares of Audentes Therapeutics stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $30.00, for a total value of $432,780.00. Following the completion of the sale, the chief executive officer now owns 127,820 shares in the company, valued at $3,834,600. The disclosure for this sale can be found here. Corporate insiders own 5.30% of the company’s stock.
Several institutional investors have recently made changes to their positions in BOLD. Dupont Capital Management Corp purchased a new position in shares of Audentes Therapeutics in the second quarter worth about $745,000. Prudential Financial Inc. grew its stake in Audentes Therapeutics by 272.3% during the 2nd quarter. Prudential Financial Inc. now owns 78,218 shares of the biotechnology company’s stock valued at $2,961,000 after acquiring an additional 57,210 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in Audentes Therapeutics by 7.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 241,100 shares of the biotechnology company’s stock valued at $6,772,000 after acquiring an additional 17,483 shares during the last quarter. Altshuler Shaham Ltd acquired a new stake in Audentes Therapeutics in the 2nd quarter valued at about $669,000. Finally, Voloridge Investment Management LLC acquired a new stake in Audentes Therapeutics in the 2nd quarter valued at about $993,000. 98.08% of the stock is owned by institutional investors and hedge funds.
About Audentes Therapeutics (NASDAQ:BOLD)
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Recommended Story: What is the Moving Average Convergence Divergence (MACD) oscillator?
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.